References
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.
Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.
Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40:8–13.
Chayama K, Hayes CN, Ohishi W, Kawakami Y. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1–12.
Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.
Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.
Conflict of interest
Dr. N. Kawada has received grants from MSD K.K. and Chugai Pharmaceutical Co., Ltd.
Author information
Authors and Affiliations
Corresponding author
Additional information
An answer to this letter to the editor is available at doi:10.1007/s00535-013-0760-y.
Rights and permissions
About this article
Cite this article
Enomoto, M., Tamori, A., Kobayashi, S. et al. Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for ‘middle’?. J Gastroenterol 48, 555–556 (2013). https://doi.org/10.1007/s00535-013-0759-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-013-0759-4